This means that passive immunization with tau antibodies is often a feasible therapeutic target and the CSF standard of p-tau262/356 or with the microtubule binding area (MTBD) can function a helpful biomarker of tau pathology to observe tau therapeutics in medical trials.To Jubao Duan from the University of Chicago, the authors offer persuasive pr